The CHMP meeting will take place next week April 23-26, we have no idea what day exactly is SRPT meeting, (Update 04/23: today the CHMP published this week agenda and SRPT Oral-Explanation set on 04/24 at 8:00 EST) . Usually after the Oral-Explanation the CHMP will ask the applicant representatives to step out from the […]
SRPT – Preparing For The CHMP Oral-Explanation
It was an intense week for SRPT’s investors, where the share price bounced from $74.36 (close Friday 03/09) to reach the high of $84.37 this week after the press release from Sarepta getting the green light from the FDA for Golo accelerated approval pathway (AA), and preparing to start the rolling NDA submission. Followed with […]
SRPT Was and Still The DMD Gene Therapy Leader
Today after the market close, Solid Biosciences (SLDB) announced it has received notification from the U.S. Food and Drug Administration (FDA) that IGNITE DMD, its Phase I/II clinical trial for SGT-001 microdystrophin gene transfer in Duchenne muscular dystrophy (DMD), has been placed on Clinical Hold. The news sent SLDB share price down to $11.90 or […]
Sarepta Official Statement Regarding The UK Study Halt
This morning, EP Vantage reported a temporary UK study halt in dosing after “one serious adverse event that could possibly be related to the investigational drug product” but the halt was for the UK only and did not include any other clinical trial which include Belgium, Czechia, France, Germany, Israel, Italy, Spain, Sweden, and the United States. […]
Dr. James Wilson Paper About Safety Concerns, Is Not Sarepta’s Concern!
Today morning, most of the gene-therapy stocks including SLDB, AVXS, ONCE, RGNX, BOLD, ABEO and even SRPT Stumbled following Dr. James Wilson paper published online “Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an AAV vector expressing human SMN” (link to the paper) highlighting the toxicity in NHP- non-human primate study. […]
A Quick Technical Look At SRPT Full Year Chart
Sarepta Therapeutics, Inc. (SRPT) Nasdaq A quick look at Sarepta’s yearly chart, from the spike to $63.73 after Exondys-51 FDA approval and the drop to $26.66 lowest point by Dec 30th, the last trading day of 2016. What is important to watch is the big picture, as we are right now above the Fibo-50% retracement […]
SRPT – Preparing For Blast Of Catalysts
Already a year has passed since Sarepta’s first drug Exondys51 was granted FDA approval on 09/19/2016. The landmark decision by Janet Woodcock, despite the review team’s opposition, gave hope to all the kids with DMD (Duchenne Muscular Dystrophy) Exondys51 is in the middle of a great launch, one of the most successful first-year launches of […]
A Deep Dive in SRPT Chart!
Sarepta Therapeutics, Inc. (SRPT) -Nasdaq During the past six weeks we had so many stories, with or against SRPT approval, where a 10-million shares short sellers are still traped in this name with a significant loss after the FDA approval, and they are trying nonstop any way or attack to find a way to make […]
TRIL – A quick update from BloomBurton 2016 conference
Trillium Therapeutics Inc. (TRIL) – Nasdaq Trillium Therapeutics (TRIL) presented at BloomBurton-2016 Healthcare Investor Conference in Toronto on May 3rd, the same as last year the speaker was TRIL’s Chief Scientific Officer (CSO) Dr. Bob Uger, he took the stand in Hall A (the largest room at the conference) that was full with investors, press […]
SRPT – Final thoughts ahead of the AdCom
Reaching the decision point… Today is the day we have to make decisions in SRPT position. As has been explained several times in the forum and CRG twitter private feed, the date of the panel is 04/25 and the FDA BD comes two days before the preliminary panel (2 business days), it should be […]
SRPT – YEAR 4 DATA ANALYSIS
YEAR 4 DATA ANALYSIS Review of Eteplirsen to treat DMD By: @boscaptn, et al. Compiled From SAREPTA Public Data For Week 216 (Year 4) of Study 201/202 for Exon 51 Disclaimer: NO FINANCIAL ADVICE – The Information in this report is provided for education and informational purposes only, without any express or […]
Biotech Inflection Point – Watch List-2
Following my last technical analysis “Biotech Inflection Point – Watch List-1” I will keep adding names to our watch list with some beaten down tickers, we can find many deep value biotech stocks in the recent pullback, some are trading at or very close to their cash level, at this point their assets are […]
Biotech Inflection Point – Watch List-1
Following my last technical analysis “XBI – A Look At The Near and Long Term In The Biotech Sector” I will start adding names to our watch list with some beaten down tickers, we can find many deep value biotech stocks in the recent pullback, some are trading at or very close to their cash […]
XBI – A Look At The Near and Long Term In The Biotech Sector
SPDR S&P Biotech ETF (XBI)–NYSE We will maintain our focus on the XBI as the biotech barometer, many are waiting for the XBI to outperform the IBB again and lead the way to a real recovery, to give us the sign that the technical correction is done and we are back to a […]
The XBI In The Take Or Break Zone!
SPDR S&P Biotech ETF (XBI)–NYSE We will maintain our focus on the XBI as the biotech barometer. After the double bottom around 59 points a month ago, the XBI start printing a higher high and a higher low, the first step in the new uptrend that we are looking for. Looking again at […]
Sarepta Patent Issue – Ask The USPTO Reg Attorney
This week BioMarin (BMRN) announced it won the first DMD patent battle against Sarepta (SRPT) in a press release stating, "BioMarin Receives Favorable Ruling in the Use of Exon 51 Antisense Oligonucleotides Patent Interference". On the other hand, Sarepta press release said, "Sarepta Therapeutics Announces USPTO Decision in Patent Interference Case with BioMarin Pharmaceutical" […]
2 Biotech Stocks In The Breakout Territory
Biotech traders have to adapt to any changes in the stock market, trying to adjust their trades and the game plan along with the markets condition. It is easier to take swing trades, long or short during a bull or bear market, but lately the choppiness and indecision hurt both longs and the shorts […]
SRPT Breakout- A Quick Look At The Chart
Sarepta Therapeutics, Inc. (SRPT) – Nasdaq After three years of a roller coaster, Sarepta getting closer to the the real deal, started with the NDA acceptance by the FDA on August 25th and a PDUFA date set on Feb 26th, 2016, but still waiting for the final date of the FDA Advisory Committee (AdCom) that […]
A Quick look – XBI In The Decision Zone
SPDR S&P Biotech ETF (XBI) We will maintain our focus on the XBI as the biotech barometer. Noticing lately the fact XBI is outperforming the IBB & the broader market SPY or SPX, might give us the sense that investors are again, willing to take more risk with the small-mid cap biotech companies after the […]
BioBlast Pharma: an under the radar ultra-rare disease company
Bio Blast Pharma Ltd. (ORPN) – Nasdaq BioBlast Pharma (ORPN) is a clinical-stage biotech company, focused on treatments for rare and ultra-rare diseases, especially genetic and metabolic diseases. The company has three diversified platforms currently address five different diseases. The platforms include Cabaletta, which is a platform for diseases characterized by mutated proteins; BBrm platform is a […]
